Therefore, we believe that the combined treatment of exogenous p53 and cisplatin changed the metabolic pattern of non-small-cell lung cancer A549 cells by regulating the TIGAR, increased the mitochondrial pathway apoptosis, and thus increased the sensitivity to cisplatin. Here, TP53 is linked to non-small cell lung carcinoma.